Antengene Licenses ATG-201 to UCB in $1.1B Deal

Innovative biotech firm Antengene Corporation Limited has entered into a major global licensing agreement with biopharmaceutical company UCB to advance the development of ATG-201, a novel T-cell engager therapy aimed at treating immune-related diseases. The partnership grants UCB worldwide exclusive rights to further develop, manufacture, and commercialize the investigational therapy while also providing access to the associated manufacturing technology.

ATG-201 is designed as a CD19-targeting bispecific T-cell engager (TCE), a class of therapies that activate the immune system to eliminate specific disease-causing cells. These therapies are particularly promising for diseases driven by abnormal B cells, including autoimmune disorders and certain blood cancers. The drug works by simultaneously binding to CD3 on T cells and CD19 on B cells, directing the immune system to attack and eliminate CD19-expressing B cells.

According to the companies, ATG-201 incorporates steric hindrance masking technology, an approach intended to enhance safety and precision. This design helps limit immune activation until the drug binds to the intended target cells, potentially reducing risks such as cytokine release syndrome (CRS), a serious immune-related side effect often associated with T-cell-engaging therapies.

Antengene plans to file clinical trial applications for ATG-201 in China and Australia during the first quarter of 2026. The company will conduct first-in-human Phase I clinical trials in both countries before transferring further clinical development and global advancement responsibilities to UCB.

Jay Mei, founder, chairman, and chief executive officer of Antengene, said the collaboration combines the company’s discovery capabilities and clinical development expertise with UCB’s deep experience in immunology. He noted that ATG-201 has been specifically engineered for autoimmune diseases using a bivalent CD19-binding strategy, proprietary CD3 sequences, and steric hindrance-based masking technology to enhance B-cell depletion while potentially minimizing immune-related toxicity.

The therapy was developed using Antengene’s proprietary AnTenGager™ platform, which focuses on next-generation T-cell engager technologies. The platform uses steric masking to control the activation of the CD3-binding arm of the molecule until it encounters a disease-associated antigen, which may improve tolerability and maintain strong therapeutic activity.

UCB executives highlighted the strategic importance of gaining access to the technology. Alistair Henry, chief scientific officer of UCB, said the agreement aligns with the company’s ambition to strengthen its leadership in immunology. He added that the partnership complements UCB’s existing expertise in monoclonal antibodies and biologics while expanding its capabilities into bispecific T-cell engager therapies.

Financially, the deal includes an upfront and near-term milestone package valued at $80 million for Antengene, consisting of a $60 million initial payment and an additional $20 million tied to near-term milestones. Antengene may also receive more than $1.1 billion in potential development and commercial milestone payments if the therapy progresses successfully. In addition, the company will be eligible for tiered royalties on future net sales of any approved products.

Researchers at Antengene say the AnTenGager platform could also support the development of additional therapies targeting solid tumors and hematological malignancies. The partnership with UCB is expected to accelerate the global development of ATG-201 and potentially bring a new treatment option to patients with immune-mediated diseases.